CP 55,940 is a non-selective, synthetic agonist of the cannabinoid receptors. It has shown activity in anti-cancer, anti-nociceptive, anti-hyperalgesic and anti-neurodegenerative capacity. More recent studies demonstrated the ability of CP 55,940 to decrease cancer-related pain in mouse models. In mice models with induced hyperalgesia, CP 55,940 administration improved the response of mice in a paw-withdrawal assay. In CB1 knockout mice, CP 55,940 decreased the amount of allodynia pain in a paclitaxel-induced neuropathy.